> Michael Hanack (the materials chemist) used a different strategy: he would not patent anything so his inventions could be used my any market participant, and he would consult for all of them.
That won't work if the invention is easily copied. Chemistry is tricky and there's probably plenty of money to be made in consulting in it. A lot of industries aren't like that.
In the sciences you'll notice that simultaneous discoveries are nothing unusual, once the groundwork is laid the idea hangs in the air, you do nothing but reach out and catch it. The Zuse example is just another instance.
In the case of mathematics and computing, the invention can be copied easily by development costs are minimal as well. These is no compelling reason why someone should reap disproportionate rewards from a government-supported artificial monopoly. Progress suffers and the economy as well.
Yes there is: because of the effort of invention. The effort required to copy is irrelevant. Also, by arguing against patents, you're basically arguing that Intel and the like should get a huge payday at the expense of this guy's efforts.
Patents only last for 20 years [1], and it's not like progress stops when they're in force. Have some patience.
Offering an alternative to that is why the patent system was created. The idea is you publish and in return get a monopoly for a short period of time. Of course the system is abused (all systems are abused), but the reasons for its creation were actually quite "liberal."
Apparently, there were design reasons why for electronic calculations a different mathematical formulation was more efficient. The competing manufacturers would discover this fact one by one, and Zuse was worried that someone may question his integriry, thinking he was the source of the leak. But no one did.
Michael Hanack (the materials chemist) used a different strategy: he would not patent anything so his inventions could be used my any market participant, and he would consult for all of them.
On the other hand, everyone is looking forward to the day the aptamer patent runs out. Uptake is limited (and you'd think that CRISPR/CAS9 has the same problem) because of unreasonableness (in case of CRISPR uncertainty) around licensing.